Punishment is the only other procedure that has yielded durable response
Good response rate and durable response
, especially those associated with Cis, were noted.
subcutaneous GM-CSF had significantly improved rates of durable response
, defined as responses lasting 6 months or more, (16.
Although front-line combination chemotherapy can result in durable response
rates, up to 30 percent of these patients relapse or are refractory to front-line treatment and have few therapeutic options beyond ASCT.
The authors noted that treatments could become cost effective if drug prices were to drop significantly, or if clinical trials could establish whether a durable response
was possible without continued therapy.
1 months, which is similar to the time to response for dacarbazine), and a durable response
(the median duration of response was not reached but the duration of follow-up was short)," the investigators said.
Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: As we have seen in other studies, durvalumab has demonstrated expected clinical activity and durable response
in these heavily pre-treated patients.
Secondary endpoints include response duration, disease control at 3 months, percent progression-free survival (PFS) at 6 months, durable response
6 months, and time-to-progression (TTP).
Final data on survival and durable response
from AGENDA are expected in the first half of 2011.
And earlier this month, at ASCO-GU, an updated analysis from the trial evaluating cabozantinib, in combination with nivolumab or with nivolumab plus ipilimumab, demonstrated high rates of durable responses
in patients with previously treated metastatic urothelial carcinoma and metastatic RCC.
The durable responses
observed with KEYTRUDA monotherapy in this difficult-to-treat cancer are encouraging.
A small study released earlier this month showed that combining Merck's Keytruda with an experimental IDO1 drug from Incyte Corp led to a high rate of durable responses
in patients with advanced lung cancer.
Talking about the possibility of combination therapy he added, "It is possible that with effective combination strategies we could see dramatic improvements in the proportion of patients who have durable responses
with immune checkpoint inhibitors.
Currently approved targeted therapies have been unable to produce durable responses
in RCC patients and only delay progression.
Patients receiving elvitegravir 125 mg had rapid viral load declines; those with at least one active drug in their background therapy had durable responses
(mean decline in HIV-1 RNA of 2.